You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Trove at the National Library of Australia has information on archived TGA consultations and reviews.
Filters
Status
Categories
- Remove Advertising filter Advertising (2)
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Complementary medicines (7) Apply Complementary medicines filter
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Remove Listed medicines filter Listed medicines (2)
- Remove Manufacturing filter Manufacturing (1)
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Remove Medical devices safety filter Medical devices safety (1)
- Remove Medicinal cannabis filter Medicinal cannabis (1)
- Medicines (2) Apply Medicines filter
- Remove Medicines safety filter Medicines safety (1)
- OTC medicines (12) Apply OTC medicines filter
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Prescription medicines (7) Apply Prescription medicines filter
- Scheduling (56) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Remove Therapeutic goods regulation filter Therapeutic goods regulation (2)
- (-) Remove Therapeutic goods regulation filter Therapeutic goods regulation
- (-) Remove Manufacturing filter Manufacturing
- (-) Remove Medical devices safety filter Medical devices safety
- (-) Remove Medicinal cannabis filter Medicinal cannabis
- (-) Remove Listed medicines filter Listed medicines
- (-) Remove Advertising filter Advertising
- (-) Remove Medicines safety filter Medicines safety
Improving access to medicine adverse event data - sponsor survey
Closed on 18 February 2022
Proposed changes to the Permissible Ingredients Determination: Low-negligible risk changes 2021-22
Closed on 15 September 2021
Proposed improvements to the Therapeutic Goods Advertising Code
Closed on 18 June 2021
Potential reforms to medicinal cannabis manufacturing, labelling and packaging requirement
Closed on 29 January 2021
IMDRF consultation: Proposed update to document on Post-Market Clinical Follow-Up Studies
Closed on 11 December 2020
Changes to permissible ingredients - Low-negligible risk
Closed on 11 October 2019
Proposed clarification that goods are therapeutic goods - goods containing folate substances in certain circumstances
Closed on 18 September 2019
Options for the future regulation of 'low risk' products
Closed on 12 May 2017